What question did this study set out to answer?

The review aims to clarify the frequency, evaluation, and management of hyperaldosteronism in hypertension.

March 1, 2003Current Opinion in Nephrology & Hypertension

Aldo is back: recent advances and unresolved controversies in hyperaldosteronism

View Full Paper

Ask AI

Bookmark

The review aims to clarify the frequency, evaluation, and management of hyperaldosteronism in hypertension.
Summarized recent literature on hyperaldosteronism prevalence in hypertensive populations.
Discussed diagnostic criteria and treatment options for hyperaldosteronism.
Highlighted the role of adrenal vein sampling in severe cases.
Approximately 10% of hypertensive patients have hyperaldosteronism, although aldosterone-producing adenomas are rare.
Mineralocorticoid antagonism, such as eplerenone, shows exceptional efficacy in patients with mild hyperaldosteronism.
Aldosterone excess is linked to cardiotoxic and nephrotoxic effects, emphasizing the need for mineralocorticoid blockade.

Structured PICO

Population

Hypertensive patients with suspected or confirmed hyperaldosteronism

Intervention

Mineralocorticoid receptor antagonists (e.g., eplerenone) and selective adrenal vein sampling

Hyperaldosteronism is a common secondary cause of hypertension that may benefit significantly from targeted mineralocorticoid receptor antagonism.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Supports mineralocorticoid blockade for cardiorenal protection beyond BP lowering; leaves open optimal screening and outcome confirmation in prospective trials.

Cite This Study

Richard J. Auchus (2003) studied this question.

synapsesocial.com/papers/6a74d9070081fe7b05dbef13 https://doi.org/10.1097/00041552-200303000-00005

Topics

Hypertension management

View Full Paper

Ask AI

Bookmark

Implication

Supports mineralocorticoid blockade for cardiorenal protection beyond BP lowering; leaves open optimal screening and outcome confirmation in prospective trials.

Aldo is back: recent advances and unresolved controversies in hyperaldosteronism

Key Points

Structured PICO

Discussion

Implication

Cite This Study

Topics

Aldo is back: recent advances and unresolved controversies in hyperaldosteronism

Key Points

Structured PICO

Discussion

Implication

Cite This Study

Also Consider

Topics

Also Consider